Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?

Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Debourdeau P, Elalamy I, de Raignac A, Meria P, Gornet JM, Amah Y, Korte W, Marty M, Farge D. Author information Abstract INTRODUCTION: Cancer disease inducing an acquired hypercoagulable state is a well-established feature. Venous thromboembolism (VTE) occurs in 4% to 20% of the patients and is the second cause of mortality in cancer; VTE in...
Plus